Infected blood inquiry: Government must learn from past health mistakes pressandjournal.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressandjournal.co.uk Daily Mail and Mail on Sunday newspapers.
Athens Times
The EMA approved 2 additional production Places for the Pfizer vaccine
The EMA Committee on Human Medicines (CHMP) announced that it has approved two additional production sites for Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer.
Published
The
EMA Committee on Human Medicines (CHMP) announced that it has approved two additional production sites for Comirnaty, the COVID-19 vaccine developed by
BioNTech and Pfizer.
Allergopharma GmbH & Co. KG. and the other in Stein, Switzerland and is managed by
Novartis Pharma.
The two production lines will carry out final product manufacturing steps at different stages of the process and are expected to support Comirnaty’s ongoing supply to the European Union.
Oxford Astrazeneca Covid vaccine safety briefing - latest updates somersetlive.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from somersetlive.co.uk Daily Mail and Mail on Sunday newspapers.
ON December 2, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) authorised the first Covid-19 vaccine. After so much suffering and so many deaths from the disease, alongside the harms caused by lockdowns, this was the good news. But there were still many questions. Would this vaccine and others be effective outside of clinical trials? Would they be safe when administered in the general population? Was Scotland ready for vaccine roll out? Would uptake be good enough? Would vaccines prevent transmission of the virus? Three months on, we have some answers. None of them are definitive and questions remain, particularly about the longer term. But the answers give us hope.
Met dank overgenomen van Europese Commissie (EC), gepubliceerd op vrijdag 11 december 2020.
With which companies have you concluded COVID-19 vaccine agreements?
The Commission is negotiating intensely to build a diversified portfolio of vaccines at fair prices. Contracts have been concluded with AstraZeneca (400 million doses), Sanofi-GSK (300 million doses), Johnson and Johnson (doses covering 400 million people), BioNTech-Pfizer (300 million doses), CureVac (405 million doses) and Moderna (160 million doses). Member States also have the option to donate vaccines to lower and middle income countries.
Which vaccine candidates are currently being reviewed by the European Medicines Agency?
The European Medicines Agency (EMA) has received an application for a conditional marketing authorisation for the vaccine developed by BioNTech and Pfizer and will deliver the assessment by 29 December at the latest.